Back

LINC01133 knockout increases malignancy by migration mechanisms in Hs578T Triple-Negative Breast Cancer Cells

Jesus-Ferreira, H. C.; Teodoro, L.; Carreira, A. C. O.; Sogayar, M. C.

2026-07-10 cancer biology
10.64898/2026.07.03.736417 bioRxiv
Show abstract

Long non-coding RNAs (lncRNAs) have attracted increasing interest because of their roles as modulators of tumor progression, acting either as oncogenic drivers or tumor suppressors, depending on the cellular context. LINC01133 has been implicated in regulation of multiple tumor-related mechanisms; however, its role in breast cancer, particularly in the triple-negative subtype, remains poorly characterized. In this study, we investigated the impact of LINC01133 depletion on malignant phenotypes and on the expression of migration- and invasion-associated genes using the Hs578T triple-negative breast cancer (TNBC) cell line, through comparative analyses of parental, control, and LINC01133-knockout cell lines, namely Hs578T_wt, Hs578T_ctr, and Hs578T_ko. Functional characterization included morphological analysis, growth assays, anchorage-independent colony formation, migration, invasion, and quantitative biomolecular experiments. Depletion of LINC01133 led to reduction of cell diameter, a significant increase in colony-forming capacity, and marked enhancement of migratory and invasive potential. At the molecular level, LINC01133 loss induced the expression of genes associated with extracellular matrix remodeling and cellular plasticity, including fibronectin, vimentin, integrins, FOXC1, and TWIST1, concomitant with reduced expression of ZEB1, TWIST2, and N-cadherin. Collectively, these data indicate that LINC01133 acts as a potential fine regulator of in vitro migration and invasion processes in TNBC, with its expression favoring a more asymptomatic mode of tumor progression, whereas its loss markedly enhances tumor malignancy.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Oncogene
85 papers in training set
Top 0.1%
16.8%
2
Cancers
213 papers in training set
Top 0.4%
9.6%
3
Molecular Oncology
55 papers in training set
Top 0.1%
6.7%
4
Scientific Reports
3612 papers in training set
Top 11%
6.7%
5
Cell Communication and Signaling
51 papers in training set
Top 0.1%
6.7%
6
PLOS ONE
5266 papers in training set
Top 26%
6.2%
50% of probability mass above
7
Cell Death & Disease
21 papers in training set
Top 0.1%
4.3%
8
Breast Cancer Research
36 papers in training set
Top 0.2%
4.0%
9
BMC Cancer
67 papers in training set
Top 0.7%
3.2%
10
International Journal of Molecular Sciences
494 papers in training set
Top 5%
2.6%
11
International Journal of Cancer
49 papers in training set
Top 0.4%
2.6%
12
Communications Biology
993 papers in training set
Top 9%
2.4%
13
npj Breast Cancer
23 papers in training set
Top 0.2%
2.4%
14
Frontiers in Cell and Developmental Biology
233 papers in training set
Top 2%
1.7%
15
eLife
5828 papers in training set
Top 52%
1.5%
16
Cancer Gene Therapy
11 papers in training set
Top 0.1%
1.5%
17
Cell Death Discovery
58 papers in training set
Top 1.0%
1.1%
18
Molecular Cancer Research
49 papers in training set
Top 1%
1.0%
19
Translational Oncology
21 papers in training set
Top 0.9%
0.8%
20
ACS Omega
105 papers in training set
Top 4%
0.8%
21
Frontiers in Oncology
103 papers in training set
Top 4%
0.6%
22
Cell Death & Disease
126 papers in training set
Top 4%
0.6%
23
Science Advances
1243 papers in training set
Top 33%
0.6%
24
Cell Reports
1498 papers in training set
Top 29%
0.6%
25
iScience
1154 papers in training set
Top 40%
0.6%
26
Biochemistry and Biophysics Reports
30 papers in training set
Top 2%
0.6%